Pharmacologic plaque passivation for the reduction of recurrent cardiac events in acute coronary syndromes  by Monroe, V.Stephen et al.
Pharmacologic Plaque Passivation
for the Reduction of Recurrent
Cardiac Events in Acute Coronary Syndromes
V. Stephen Monroe, MD, Richard A. Kerensky, MD, FACC, Enrique Rivera, MD,
Karen M. Smith, MD, FACC, Carl J. Pepine, MD, MACC
Gainesville, Florida
Acute coronary syndrome (ACS) is often associated with the rupture of vulnerable
atherosclerotic plaque, coronary thrombus formation, and abrupt limitation of blood flow,
leading to adverse outcomes. Passivation of vulnerable plaque represents a therapeutic concept
that has the potential to prevent or limit the magnitude of a new rupture in order to reduce
the recurrence or severity of events. Plaque passivation can be defined as a process by which
the structure or content of the atherosclerotic plaque is changed to reduce the risk of
subsequent rupture and thrombosis. This may be achieved by using strategies that address
different components of the plaque or the endothelium. The following factors can affect the
susceptibility of plaque to rupture: macrophage infiltration; accumulation of inflammatory
cells; paracrine secretion of enzymes that may cause degradation of the fibrous cap of coronary
plaque; shear stress; circadian rhythm variation in stress hormone release; and infectious
agents. The use of pharmacologic agents to reduce plaque vulnerability by passivation has
been explored. Clinical studies demonstrate that lipid-modifying agents (e.g., statins),
antiplatelet agents (acetylsalicylic acid, thienopyridines, thianopyridines, glycoprotein IIb/IIIa
inhibitors), and antithrombotic agents (unfractionated heparin and low-molecular-weight
heparin) can reduce the occurrence of acute coronary events in ACS patients. In addition,
angiographic studies suggest that statins may also promote regression of atherosclerosis.
Angiotensin-converting enzyme inhibitors, niacin, and calcium antagonists may also con-
tribute to plaque passivation. This article reviews atherosclerotic plaque development and
vulnerability and discusses some clinical studies highlighting the role of plaque passivation in
the management of ACS patients. (J Am Coll Cardiol 2003;41:23S–30S) © 2003 by the
American College of Cardiology Foundation
Acute coronary syndrome (ACS), a major cause of hospi-
talization in the U.S., includes unstable angina (UA),
non–ST-segment elevation myocardial infarction
(NSTEMI), and ST-segment elevation MI (STEMI) (1,2).
Unstable angina and NSTEMI are arbitrarily differentiated
by the presence or absence of specific cardiac markers (e.g.,
troponin I or T, creatinine kinase–myocardial band) (2).
The major cause of ACS is atherosclerotic plaque rupture or
erosion (2,3). Therefore, plaque passivation and stabiliza-
tion could be important strategies for reducing the risk and
severity of cardiac events.
Pathophysiology of atherosclerosis and plaque rupture.
Coronary atherosclerosis is a process characterized by the
accumulation of lipids, mononuclear cells, fibrous compo-
nents, and calcium in the arteries (4). It begins in early life
and progresses through adulthood, exacerbated by hyper-
tension, diabetes, hyperlipidemia, smoking, and obesity
(4–6). Vascular injury, recruitment of monocyte mononu-
clear cells, and infiltration of foam cells (lipid-laden mac-
rophages) which, in combination with T lymphocytes, form
fatty streaks, also promote lesion formation (4,5). The lipid
deposition is accompanied by smooth muscle cell migration
and proliferation. Eventually, atheromas develop within the
vascular wall as the intima grows outward, a process referred
to as positive remodeling (4,5).
Later stages of plaque development and vessel wall
modification are associated with luminal encroachment,
which progressively limits blood flow (5). A phasic pattern
of plaque disruption leads to the exposure of subendothe-
lium, platelet activation and aggregation, mural thrombus
formation, increased lipid accumulation within the damaged
intima and mural thrombus, and lesion progression over
time.
Cytokines and complement factor fragments, produced
by macrophages and foam cells, contribute to monocyte
mononuclear cell recruitment (4). In advanced-stage lesions,
reactive oxygen species and pro-oxidant enzymes increase
oxidative stress. Proteinases, including matrix metallopro-
teinases and elastolytic cathepsins, may alter the arterial
matrix, facilitating cellular migration and contributing to
plaque enlargement (Fig. 1) (4). Dying macrophages and
endothelial cells in the lesions also release oxidized choles-
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terol phospholipids and cytokines that can increase the
inflammatory response and cause further endothelial dam-
age (4). High sensitivity C-reactive protein (hs-CRP) serum
levels have been found to be independently associated with
sudden death attributable to severe atherosclerotic coronary
disease (7). Elevation of hs-CRP has also been associated
with thin cap atheromas and immunohistochemical depo-
sition of CRP within plaques. These results, reflected by
serum hs-CRP, support the concept that inflammation is an
important component of plaque instability (7).
Plaque passivation: a potential target for therapy. Passi-
vation generally refers to physical, chemical, or biological
interactions that result in the stabilization of component
surfaces. Atheromatous plaque passivation can be defined as
a process by which the structure or content of the active
atherosclerotic plaque is changed to effect a reduction in the
risk of subsequent rupture and thrombosis. This may be
achieved through various therapeutic strategies that address
different components or processes at or near the surface of
the plaque or the overlying endothelium, thereby minimiz-
ing or stabilizing vulnerable lesions that could otherwise
lead to thrombotic complications. Successful treatment
requires a thorough understanding of the complex processes
involved in plaque formation, progression, and susceptibility
to rupture. Clinical and angiographic studies have demon-
strated that lipid-modifying, antiplatelet, and antithrom-
botic agents can reduce the occurrence of acute coronary
events in ACS patients. Passivation of vulnerable plaque
represents a therapeutic strategy that can potentially prevent
or reduce the severity of new rupture.
The identification of future culprit lesions is uncertain
with current technology. A lack of significant correlation
between stenosis severity and plaque vulnerability has been
repeatedly demonstrated. For example, in about two-thirds
of cases studied, the plaques in the immediate proximity of
the thrombotic occlusion were obstructing 70% of the
lumen diameter. Also, in angiographic studies of ACS
patients, the culprit coronary artery stenosis arose from the
most severely occluded artery in only 34% of cases (8).
Another review found only 22% of infarct-related arteries
had 70% stenosis on previous angiography (9,10).
Vulnerable plaques characteristically contain a large lipid
pool, thin fibrous cap, high macrophage content, and few
smooth-muscle cells or collagen (6,11). Other factors that
increase vulnerability include macrophage infiltration, accu-
mulation of inflammatory cells, enzymatic degradation of
the fibrous cap, hemodynamic shear stress, and circadian
neurohumoral changes (6). Some infectious agents (e.g.,
cytomegalovirus, Chlamydia pneumoniae) are also thought to
be associated with plaque rupture, but a pathophysiologic
mechanism remains to be elucidated.
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
ACS  acute coronary syndrome(s)
GP  glycoprotein
hs-CRP  high-sensitivity C-reactive protein
LDL  low-density lipoprotein
LMWH  low-molecular-weight heparin
NSTEMI  non–ST-segment elevation myocardial
infarction
PCI  percutaneous coronary intervention
UA  unstable angina
UFH  unfractionated heparin
Figure 1. Metabolism of collagen and elastin in the plaque’s fibrous cap. The vascular smooth muscle cell synthesizes the extracellular matrix protein,
collagen, and elastin from amino acids. In the unstable plaque, interferon-gamma (IFN-) secreted by activated T cells may inhibit collagen synthesis,
interfering with maintenance and repair of the collagenous framework of the fibrous cap. The activated macrophage secretes proteases that can break down
both collagen and elastin to peptides and, eventually, amino acids. Breakdown of these structural molecules of the extracellular matrix can weaken the fibrous
cap, rendering it more susceptible to rupture and precipitation of an acute coronary syndrome. IFN- secreted by the T lymphocytes can, in turn, activate
the macrophage. Plaques also contain other activators of macrophages, including tumor necrosis factor-alpha (TNF-), macrophage colony-stimulating
factor (M-CSF), and macrophage chemoattractant protein-1 (MCP-1), among others. IL  interleukin. (Reprinted from Libby P, et al. Am J Cardiol
2000;86 Suppl:3J–9J. Copyright 2000, with permission from Excerpta Medica Inc., and reproduced with permission from the American Heart Association.
Libby P, et al. Molecular bases of the acute coronary syndromes. Circulation 1995;91:2844–50.)
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Pharmacologic options for plaque, platelet, and endothe-
lial passivation. Lipid-modifying agents such as statins
and nicotinic acid, as well as antiplatelet and antithrombotic
agents, reduce the incidence of acute coronary events and
have become increasingly important in ACS management
(2,6,11–16). Statins and nicotinic acid are able to prevent
rupture by stabilizing plaque and reducing the rate of
atherosclerosis progression (17–19). Angiotensin-
converting enzyme (ACE) inhibitors, and perhaps some
calcium antagonists, may also play a beneficial role in plaque
passivation (6).
Statins. The statins (3-hydroxy-3-methylglutaryl coen-
zyme A reductase inhibitors) effectively reduce low-density
lipoprotein (LDL) cholesterol levels, modestly increase
high-density lipoprotein concentrations, and reduce triglyc-
erides (16,17). Statin-mediated lowering of lipids may
stabilize vulnerable plaque by reducing levels of oxidized
lipoprotein in the plaque’s core. Oxidized LDL may induce
or increase enzymes such as collagenases, which are surface-
bound (4,19–22). Statins may also stabilize plaques and
reduce the risk of MI by improving endothelial vasodilator
function, upregulating nitric oxide synthesis, and reducing
intimal inflammation.
The ability of statins to improve endothelial function was
tested in the REduction of Cholesterol in Ischemia and
Function of the Endothelium (RECIFE) trial (20). In the
RECIFE trial, 60 patients with ACS were randomly as-
signed to placebo (n  30) or pravastatin 40 mg per day (n
 30) within approximately 10 days of hospital admission
for a duration of six weeks. Vascular endothelial cell
function was assessed by flow-mediated dilation of the
brachial artery using ultrasonography. The effect of therapy
on hemostatic factors and platelet activity was also evalu-
ated.
Pravastatin significantly reduced total cholesterol by 23%
(p  0.05) and LDL by 33% (p  0.01) (Fig. 2).
Flow-mediated vasodilation of the brachial artery was un-
changed with placebo but significantly improved with prav-
astatin (p  0.02).
The randomized, double-blind, controlled Myocardial
Ischemia Reduction with Aggressive Cholesterol Lowering
(MIRACL) trial evaluated early use of atorvastatin in
patients presenting with UA or non–Q-wave MI (23).
Between 24 and 96 h after hospital admission, patients (n
3,086) received either atorvastatin 80 mg per day or match-
ing placebo for 16 weeks. The primary outcome (death,
nonfatal acute MI, cardiac arrest with resuscitation, or
recurrent symptomatic myocardial ischemia with objective
evidence and requiring emergency hospitalization) was sig-
nificantly reduced in the atorvastatin arm compared with
placebo (14.8% vs. 17.4%; p  0.048) (23). This corre-
sponds to a 16% relative risk reduction with atorvastatin.
Other studies, using coronary angiography, have demon-
strated a reduction in plaque progression on average of more
than 30% in patients treated with a statin (24–30). These
small but significant angiographic changes were accompa-
nied by a greater reduction in clinical events than expected,
indicating that statin therapy may passivate vulnerable
plaques and prevent their development (17).
There are several ongoing studies evaluating statin ther-
apy in ACS patients. The PRavastatin Or atorVastatin
Evaluation and Infection Therapy (PROVE-IT) trial is
designed to compare the early use of pravastatin 40 mg per
day or atorvastatin 80 mg per day in 4,000 patients when
therapy is initiated within 10 days after onset of an ACS
(31). Patients will be followed up for a mean of two years.
The Pravastatin Acute Coronary Treatment (PACT) study
is evaluating early clinical outcomes in ACS patients treated
with pravastatin versus placebo within the first 24 h after the
beginning of an acute coronary event (32). (This trial was
recently stopped and presented at XIV World Congress of
Cardiology, May 15, 2002. At 30 days, there was a 12.4%
[211/1698] event rate in placebo assigned patients com-
pared with 11.6% [199/1710] in pravastatin assigned pa-
tients.) The Aggrastat to Zocor (A to Z) trial is a two-phase
study. In the first phase, treatment with the glycoprotein
(GP) IIb/IIIa inhibitor, tirofiban, plus unfractionated hep-
arin (UFH) is compared with therapy with the low-
molecular-weight heparin (LMWH), enoxaparin, in pa-
tients with UA or NSTEMI (33). In the second phase,
stabilized patients, including those with STEMI not par-
ticipating in the first phase, will be randomized to receive
Figure 2. Evolution of lipid fractions between admission and time of
randomization to placebo or pravastatin (time 0) and after six weeks of
therapy in patients with acute myocardial infarction or unstable angina. *p
 0.05; **p  0.01 vs. admission; †p  0.01 vs. placebo; and ‡p  0.01 vs.
time 0. HDL high-density lipoprotein; LDL low-density lipoprotein.
(Reproduced with permission from Lippincott Williams and Wilkins.
Dupuis J, Tardif JC, Cernacek P, et al. Cholesterol reduction rapidly
improves endothelial function after acute coronary syndromes. The
RECIFE trial. Circulation 1999;99:3227–33.)
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either simvastatin or placebo. Patients will be treated within
10 days of onset with simvastatin 40 mg per day for one
month, after which the dosage will increase to 80 mg per
day. After four months, patients in the placebo group will
receive simvastatin 20 mg per day. Follow-up will continue
until 970 primary outcome events are reached (defined as
cardiac death, MI, or rehospitalization for ACS) (33).
Antithrombotic and antiplatelet agents. When plaque
rupture occurs, the subendothelial matrix becomes exposed
to circulating platelets and coagulation factors (6). Several
platelet adhesion molecules are found in the subendothelial
protein matrix, including von Willebrand factor and colla-
gen. The adhesion process leads to platelet activation,
platelet aggregation, calcium mobilization, and platelet
degranulation (33). In the final stages of this process,
circulating fibrinogen binds to upregulated GP IIb/IIIa
receptors on platelet surfaces causing cross-linking of plate-
lets (34,35). The von Willebrand factor may also bind to GP
IIb/IIIa receptors, causing platelet cross-linking. During
platelet activation, the lipid-laden macrophages and smooth
muscle cells in the core of the disrupted plaque express
tissue factor, which, when exposed to the circulation,
activates the coagulation cascade (34). The GP IIb/IIIa
receptor blockade with inhibition of the coagulation cascade
represents an important therapeutic tool for providing
protection against these processes. Aspirin combines anti-
thrombotic and anti-inflammatory capabilities, reducing
interleukin-6, CRP, and macrophage colony-stimulating
factor, and is associated with reduced risk of cardiac events
in the early weeks after an ACS.
GP IIb/IIIa inhibitors and UFH. Clinical trials have
demonstrated that GP IIb/IIIa inhibitors yield the greatest
benefit in the ACS patient population undergoing percuta-
neous coronary intervention (PCI) (36–40).
The Chimeric 7E3 AntiPlaTelet in Unstable angina
REfractory to standard treatment (CAPTURE) trial was
the first to demonstrate a clinical benefit of the GP IIb/IIIa
inhibitor, abciximab, administered before percutaneous
transluminal coronary angioplasty in ACS patients (36).
CAPTURE was a randomized, placebo-controlled, multi-
center trial enrolling 1,265 patients with refractory angina
(recurrent myocardial ischemia despite intensive medical
therapy) (36). Patients received either abciximab (0.25
mg/kg bolus followed by continuous infusion of 10 g/min)
18 to 24 h before angioplasty and continued for 1 h after the
coronary procedure, or matching placebo. The primary
outcome was the 30-day occurrence of death from any
cause, MI, or urgent intervention for recurrent ischemia
(Fig. 3). Significantly fewer patients in the abciximab group
experienced these events than in the placebo group (11.3%
vs. 15.9%; p  0.012). The rate of MI was lower in the
abciximab group before angioplasty (0.6% vs. 2.1%; p 
0.029) as well as after the procedure (2.6% vs. 5.5%; p 
0.009) (36).
The Platelet Receptor Inhibition in Ischemic Syndrome
Management in Patients Limited by Unstable Signs and
symptoms (PRISM-PLUS) study enrolled 1,915 ACS pa-
tients who presented within 12 h of symptom onset (37).
They were randomized to receive a 48-h infusion of the GP
IIb/IIIa inhibitor, tirofiban, UFH, or tirofiban plus UFH.
After 48 h, angiography and coronary angioplasty were
performed as indicated. The primary outcome was the
composite of death from any cause, MI, or refractory
ischemia within seven days after randomization. Patients
treated with the UFH and tirofiban combination had a
lower occurrence of the composite outcome before coronary
intervention, indicating an “upstream” benefit. The risk
reduction for death or MI after 48 h was 34%. A prospective
angiographic study from the PRISM-PLUS trial showed
that the combination of tirofiban plus UFH significantly
reduced the burden of intracoronary thrombus in the culprit
lesion (p  0.022), improved the perfusion grade (p 
0.002), and decreased the severity of the obstruction (p 
0.037), compared with either tirofiban or UFH alone (38).
The Platelet IIb/IIIa in Unstable angina: Receptor Sup-
pression Using Integrilin Therapy (PURSUIT) study eval-
uated the combination of eptifibatide and UFH versus UFH
Figure 3. Time course of the primary outcome and its major components.
MI  myocardial infarction. (Reprinted with permission from Elsevier
Science. Lancet 1997;349:1429–35.)
26S Monroe et al. JACC Vol. 41, No. 4 Suppl S
Pharmacologic Plaque Passivation in ACS February 19, 2003:23S–30S
alone in 10,948 ACS patients (39). The primary outcome
was the composite of death or MI at 30 days. Patients
receiving eptifibatide derived significant benefit from treat-
ment, with an absolute 1.5% reduction in death or MI at 30
days.
The Do Tirofiban And ReoPro Give Similar Efficacy
Trial (TARGET) was a double-blind, randomized study
conducted to compare the efficacy and safety of these two
GP IIb/IIIa inhibitors in patients with ACS undergoing
PCI with stenting (40). Patients were randomized to receive
either tirofiban (n  2,398) or abciximab (n  2,411). The
primary outcome was a composite of death, nonfatal MI, or
urgent target vessel revascularization at 30 days. In the
tirofiban group, there was a higher incidence of these events
(7.6%) versus 6.0% in the abciximab group (p  0.038),
suggesting the clinical superiority of abciximab (40), al-
though this difference was not as robust after six months and
one year. A reduction in periprocedural enzymatically de-
fined by defined MI appears to be the major benefit of
abciximab. A lower rate of minor bleeding and thrombocy-
topenia was noted in the tirofiban group.
LMWH versus UFH. Low-molecular-weight heparin
represents a class of anticoagulants with several pharmaco-
logic and therapeutic advantages over UFH. Protein bind-
ing and incidence of thrombocytopenia are reduced with
LMWHs. Also, they are not inactivated by platelet factor-4,
and they do not increase platelet activation or aggregation
(no “rebound” phenomenon). The LMWHs have different
abilities to inhibit factor Xa versus IIa (ratios ranging from
1.9 to 3.8), corresponding to varying clinical efficacies
between the different agents when used to treat ACS
patients (41–44).
Two large randomized clinical trials, the Efficacy and
Safety of Subcutaneous Enoxaparin in the Non–Q-wave
Coronary Events (ESSENCE), and the Thrombolysis In
Myocardial Infarction (TIMI) IIB, have demonstrated su-
periority of enoxaparin over UFH in the treatment of ACS
patients (41–44). Follow-up data from the ESSENCE trial
demonstrated that the superiority of enoxaparin over UFH
is sustained over a one-year period, with a significant
reduction in the need for diagnostic catheterization (p 
0.036) and coronary revascularization (p  0.002) (45).
Conversely, dalteparin has demonstrated only an equiva-
lency to UFH, and nadroparin tended toward inferiority,
with a higher incidence of bleeding complications associated
with prolonged use (44) (Fig. 4).
The safety of enoxaparin in combination with GP IIb/
IIIa inhibitors at PCI was demonstrated in the National
Investigators Collaborating on Enoxaparin (NICE) studies
(46,47). The efficacy of using enoxaparin in UA/NSTEMI
patients undergoing PCI has also been explored (Fig. 5). In
a recent study, enoxaparin was administered for at least 48 h
to 451 ACS patients, 65% of whom underwent coronary
angiography within 8 h of enoxaparin treatment. When
indicated, PCI (28%) was then performed without any
additional administration of UFH or LMWH and without
laboratory monitoring of anticoagulation (48). No abrupt
closure or urgent revascularization after PCI was reported,
and the incidence of death or MI at 30 days in the PCI
group was low at 3%, which compares favorably with
historical controls. An ongoing trial, the Superior Yield of
the New strategy of Enoxaparin, Revascularization, and
GlYcoprotein IIb/IIIa inhibitors (SYNERGY), is a very
large (8,000 patients) randomized trial that seeks to defin-
itively determine if enoxaparin is superior to UFH during
PCI.
ACE inhibitors. Angiotensin II affects several physiologic
components of the vascular system that contribute to plaque
instability. It may cause endothelial dysfunction, contribut-
ing to the formation of atherosclerotic lesions. It induces the
expression of vascular cell adhesion molecule-1, promoting
Figure 4. A clinical efficacy summary: low-molecular-weight heparin
(LMWH) vs. unfractionated heparin (UFH). ESSENCE  Efficacy and
Safety of Subcutaneous Enoxaparin in Non–Q-wave Coronary Events trial;
FRAXIS FRAXiparine in Ischemic Syndromes trial; FRIC FRagmin
In unstable Coronary artery disease trial; MI  myocardial infarction; NS
 not significant; RRR  relative risk reduction; TIMI  Thrombolysis
In Myocardial Infarction. (Adapted [with permission from Thieme Pub-
lishers, 2002] from Semin Thromb Hemost 1999;25 Suppl 3:113–21
[Figure 3]).
Figure 5. Percutaneous coronary intervention: 30-day clinical outcome
with enoxaparin. MI  myocardial infarction. (Reproduced with permis-
sion from Lippincott Williams and Wilkins. Collet JP, Montelscot G,
Lisbon L, et al. Percutaneous coronary intervention after subcutaneous
enoxaparin pretreatment in patients with unstable angina. Circulation
2001;103:658–62.)
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adhesion of monocytes to endothelial cells and the forma-
tion of oxygen free radicals. These all contribute to proin-
flammatory processes and plaque destabilization (49,50).
Angiotensin-converting enzyme inhibitors or angiotensin II
receptor blockers may encourage plaque stability and reduce
cardiac events. Promising animal-model studies have
prompted a number of clinical trials to examine the role of
these agents on surrogate outcomes in patients with coro-
nary atherosclerosis. The outcomes include improvement of
endothelial function determined by vascular response to
acetylcholine, B-mode ultrasound evaluation of atheroscle-
rotic progression in the carotid artery, and progression of
coronary artery disease using quantitative coronary angiog-
raphy (50).
The Study to Evaluate Carotid Ultrasound changes in
patients treated with Ramipril and Vitamin E (SECURE)
was a substudy of the Heart Outcomes Prevention Evalua-
tion (HOPE) trial (51,52). This analysis examined 732
patients from the HOPE trial who had vascular disease or
diabetes with at least one other risk factor. Subjects with
heart failure or a low left ventricular ejection fraction were
excluded. Patients receiving ramipril 10 mg per day dem-
onstrated a significant reduction in the rate of carotid
intimal medial thickening, when compared with either 2.5
mg ramipril or placebo, suggesting a beneficial negative
effect on atherosclerotic progression (51).
The Trial on Reversing ENdothelial Dysfunction
(TREND) was a multicenter, double-blind, randomized,
placebo-controlled trial that evaluated the effect of quinapril
on endothelial dysfunction in the epicardial coronary arter-
ies (53). Subjects were normotensive with no left ventricular
dysfunction, but they had one or two coronary arteries with
50% diameter stenosis and a need for coronary revascu-
larization. Twelve hours to 72 h after successful coronary
intervention, patients randomly received either placebo (n
54) or a titrated dose of quinapril (n  51) (10 mg on day
one, increased to 20 mg per day for one week, and to 40 mg
per day for six months). With quinapril, the constrictive
response to acetylcholine was significantly reduced com-
pared with placebo (p  0.014) (Fig. 6). A substudy of the
TREND trial also suggested an improvement in quantita-
tive coronary blood flow in patients receiving quinapril (54).
Calcium antagonists. There is a significant increase in
transmembrane calcium transport in atherosclerotic vessels,
which suggests that calcium antagonists may delay the pro-
gression of coronary atherosclerosis. The dihydropyridine-type
calcium antagonist, amlodipine, has shown an inhibitory
effect on oxidative alteration to lipids associated with cellular
membranes both in vitro and in vivo (55). Amlodipine may
contribute to plaque passivation by interfering with lipid
oxidative processes, limiting foam cell formation and other
cellular mechanisms that contribute to the development of
atherosclerosis (55). In the Prospective Randomized Eval-
uation of the Vascular Effects of Norvasc Trial (PRE-
VENT), the effects of amlodipine on the development and
progression of atherosclerotic lesions in coronary and ca-
rotid arteries in 825 patients with coronary artery disease
were evaluated. The PREVENT study demonstrated a
reduction in hospitalizations for revascularization and UA
with amlodipine. By ultrasonographic analysis, amlodipine
was associated with a significant delay in the progression of
carotid atherosclerosis over three years (p  0.007) (56).
The Coronary Angioplasty Amlodipine Restenosis Study
(CAPARES) was conducted in a similar patient population
and demonstrated that amlodipine significantly reduced the
occurrence of revascularization and clinical events after
angioplasty without reducing luminal loss (57).
Other agents. Other agents that may contribute to plaque
passivation include antioxidants such as vitamins C and E,
which may inhibit the oxidation of LDL cholesterol and
stabilize vascular reactivity. However, studies conducted so
far have not shown any consistent benefit in the use of
antioxidant vitamins for the treatment or prevention of
coronary atherosclerosis (52,58).
The High-density lipoprotein-Atherosclerosis Treatment
Study (HATS) studied the effect of niacin, a potent agent
for raising high-density lipoprotein cholesterol levels, in
combination with simvastatin. In patients with coronary
disease and low levels of high-density lipoprotein, this
combination produced a 0.4% regression in coronary steno-
sis (p  0.001) (58). The primary outcome of HATS was a
composite of coronary death, nonfatal MI, stroke, or revas-
cularization for worsening ischemia. With the niacin-
simvastatin therapy, the event rate was significantly lower
than with placebo (3% vs. 24%; p 0.03), corresponding to
a 90% reduction in the risk for the primary outcome. These
findings support those of the Familial Atherosclerosis
Treatment Study (FATS), which showed that intensive
lipid modification with lovastatin and niacin reduced the
Figure 6. The Trial on Reversing Endothelial Dysfunction (TREND)
investigated the effects of six months of treatment with the ACE inhibitor
quinapril on a target coronary artery segment (40% diameter stenosis) in
patients who underwent nonsurgical interventions for 50% stenosis in
one to two other segments. At baseline, the endothelium-dependent
vasodilator acetylcholine elicited a paradoxical vasoconstriction; quinapril
resulted in a significant improvement in the response to acetylcholine (p 
0.014 vs. placebo). (Reprinted from Pepine JC, et al. Improved endothelial
function with angiotensin-converting enzyme inhibitors. Am J Cardiol
2002;79:29–32. Copyright 2002, with permission from Excerpta Medica
Inc.)
28S Monroe et al. JACC Vol. 41, No. 4 Suppl S
Pharmacologic Plaque Passivation in ACS February 19, 2003:23S–30S
occurrence of clinical events by 73% and lowered the
progression of coronary lesions, with some evidence of
regression in existing lesions (59).
Mechanical approaches. Traditionally, PCI has been re-
served for lesions causing luminal stenosis resulting in
myocardial ischemia. Mechanical coronary intervention is
also performed during or after MI or ACS to treat lesions
that have already produced thrombi. The concept of using
PCI for plaque passivation has not been discussed in the
usual paradigm of invasive cardiology. Before the advent of
coronary stenting, balloon angioplasty probably increased
the instability of previously stable plaques. With the devel-
opment of coronary stenting, however, plaque stabilization
could be achieved by covering the eroded surface with the
stent struts and mechanically creating a larger luminal area
for improved blood flow.
Even with the latest technology, stents are not currently
used to stabilize non-occlusive, vulnerable lesions. The
reasons for this are twofold. First, the vulnerable plaque
cannot be identified easily with current imaging techniques.
Second, stenting with bare metal stents is inappropriate
because thrombosis can occur and intimal hyperplasia will
cause restenoses in some cases. Future percutaneous me-
chanical plaque passivation will require the development of
techniques for the identification of high-risk plaque even
when it is not obstructing the vessel lumen. Also, biologi-
cally neutral or coated stents with drug-delivery capabilities
need to be developed. This would allow delivery of an agent
that will inhibit the intimal hyperplasia associated with stent
insertion. Such a concept is appealing only if stent-induced
stenosis can be prevented; otherwise, this approach will lead
to an exchange of vulnerable non-obstructive plaques for
stenotic in-stent hyperplastic lesions. Because coronary
atherosclerosis is a diffuse process, the application of local
therapies such as covered, drug-eluting stents is likely to
have limited application, but one can envision the use of
percutaneous therapy to passivate the highest-risk plaques
even before they cause an angiographic stenosis.
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